Eli Lilly and Company is a fundamentally solid pharma major with sufficient time on its hands to build its pipeline before patent expiry on its key drugs. The company had fairly good 2021 year with strong top as well as bottom-line growth across each of its five vital assets. The management has put its cash flow to work for creating a long-term plan, and lately, it has announced plans to make important investments in new manufacturing sites in both Ireland and North California. These investments ....
16 Apr 2022
Eli Lilly and Company: Detailed Credit Analysis & Financial Strength Evaluation Report, Key Risks & ESG Assessment (04/2022)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Eli Lilly and Company: Detailed Credit Analysis & Financial Strength Evaluation Report, Key Risks & ESG Assessment (04/2022)
- Published:
16 Apr 2022 -
Author:
Ishan Majumdar -
Pages:
17
Eli Lilly and Company is a fundamentally solid pharma major with sufficient time on its hands to build its pipeline before patent expiry on its key drugs. The company had fairly good 2021 year with strong top as well as bottom-line growth across each of its five vital assets. The management has put its cash flow to work for creating a long-term plan, and lately, it has announced plans to make important investments in new manufacturing sites in both Ireland and North California. These investments ....